Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-Step RIC Allo-HSCT for High-Risk Hematologic Malignancies
NCT01760655Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2012
- Primary completion
- Apr 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of donor lymphocyte infusion in hematologic malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2012; status: completed.
02
Drugs
donor lymphocyte infusion
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT01760655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760655.